title: The effects of nucleus accumbens μ-opioid and adenosine 2A receptor stimulation and blockade on instrumental learning.
abstract: Prior research has shown that glutamate and dopamine receptors in the nucleus accumbens (NAcc) core are critical for the learning of an instrumental response for food reinforcement. It has also been demonstrated that μ-opioid and adenosine A2A receptors within the NAcc impact feeding and motivational processes. In these experiments, we examined the potential roles of NAcc μ-opioid and A2A receptors on instrumental learning and performance. Sprague-Dawley rats were food restricted and trained to lever press following daily intra-accumbens injections of the A2A receptor agonist CGS 21680 (at 0.0, 6.0, or 24.0ng/side), the A2A antagonist pro-drug MSX-3 (at 0.0, 1.0, or 3.0μg/side), the μ-opioid agonist DAMGO (at 0.0, 0.025, or 0.025μg/side), or the opioid receptor antagonist naltrexone (at 0.0, 2.0 or 20.0μg/side). After five days, rats continued training without drug injections until lever pressing rates stabilized, and were then tested with a final drug test to assess potential performance effects. Stimulation, but not inhibition, of NAcc adenosine A2A receptors depressed lever pressing during learning and performance tests, but did not impact lever pressing on non-drug days. Both μ-opioid receptor stimulation and blockade inhibited learning of the lever-press response, though only naltrexone treatment caused impairments in lever-pressing after the task had been learned. The effect of A2A receptor stimulation on learning and performance were consistent with known effects of adenosine on effort-related processes, whereas the pattern of lever presses, magazine approaches, and pellet consumption following opioid receptor manipulations suggested that their effects may have been driven by drug-induced shifts in the incentive value of the sugar reinforcer.
authors.affiliation: Department of Psychology, Wake Forest University, Winston-Salem, NC, United States. Electronic address: kaclissold@gmail.com.
authors.forename: Kara A
authors.initials: KA
authors.lastname: Clissold
authors.affiliation: Department of Psychology, Wake Forest University, Winston-Salem, NC, United States. Electronic address: prattwe@wfu.edu.
authors.forename: Wayne E
authors.initials: WE
authors.lastname: Pratt
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D008297:Male; D008845:Microinjections; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D058906:Purinergic P1 Receptor Agonists / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043705:Receptor, Adenosine A2A / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000378:metabolism*; D013997:Time Factors
chemical_list: D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D058906:Purinergic P1 Receptor Agonists; D043705:Receptor, Adenosine A2A; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009271:Naltrexone
keywords: Adenosine; Learning; Motivation; Nucleus accumbens; mu-Opioid receptor
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2002 Nov;366(5):478-81
references.pmid: 12382078
references.citation: J Neurosci. 1997 Jun 1;17(11):4434-40
references.pmid: 9151760
references.citation: Behav Neurosci. 2006 Jun;120(3):542-53
references.pmid: 16768606
references.citation: J Neurosci. 2008 Sep 3;28(36):9037-46
references.pmid: 18768698
references.citation: Biol Psychiatry. 2013 May 1;73(9):843-50
references.pmid: 23312563
references.citation: Behav Brain Res. 2002 Dec 2;137(1-2):149-63
references.pmid: 12445721
references.citation: Pharmacol Biochem Behav. 2010 Nov;97(1):144-51
references.pmid: 20562021
references.citation: Neuroscience. 2014 Mar 7;261:144-52
references.pmid: 24342569
references.citation: J Neurosci. 1995 Oct;15(10):6779-88
references.pmid: 7472436
references.citation: J Neurosci. 2005 Dec 14;25(50):11777-86
references.pmid: 16354936
references.citation: Brain Res. 1995 Nov 27;700(1-2):205-12
references.pmid: 8624711
references.citation: Behav Neurosci. 2004 Aug;118(4):730-9
references.pmid: 15301600
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16335-40
references.pmid: 17913892
references.citation: J Neurosci. 2000 Oct 15;20(20):7737-42
references.pmid: 11027236
references.citation: Physiol Behav. 2000 Jul 1-15;70(1-2):95-103
references.pmid: 10978483
references.citation: Behav Neurosci. 2003 Apr;117(2):202-11
references.pmid: 12708516
references.citation: Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12174-9
references.pmid: 9342382
references.citation: J Neurosci. 1997 Jun 15;17(12):4839-48
references.pmid: 9169542
references.citation: J Biol Chem. 2003 Nov 21;278(47):46741-9
references.pmid: 12933819
references.citation: Physiol Behav. 2007 Aug 15;91(5):506-12
references.pmid: 17316713
references.citation: Behav Neurosci. 2009 Oct;123(5):1046-57
references.pmid: 19824770
references.citation: Neuropharmacology. 1986 Oct;25(10):1141-7
references.pmid: 3785582
references.citation: Brain Res. 2000 Sep 8;876(1-2):76-87
references.pmid: 10973595
references.citation: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7877-82
references.pmid: 16684876
references.citation: Behav Brain Res. 2007 Mar 28;178(2):190-9
references.pmid: 17223207
references.citation: Curr Pharm Des. 2008;14(15):1468-74
references.pmid: 18537670
references.citation: J Pharmacol Exp Ther. 1996 Sep;278(3):1499-507
references.pmid: 8819538
references.citation: Psychopharmacology (Berl). 2008 Sep;199(4):515-26
references.pmid: 18491078
references.citation: Braz J Med Biol Res. 2002 Oct;35(10):1201-8
references.pmid: 12424493
references.citation: Neuroscience. 2010 Apr 14;166(4):1056-67
references.pmid: 20096336
references.citation: Neuroscience. 2006 Nov 17;143(1):309-17
references.pmid: 17049180
references.citation: J Neurosci. 2001 May 1;21(9):3261-70
references.pmid: 11312311
references.citation: Eur J Neurosci. 2003 May;17(10):2187-200
references.pmid: 12786986
references.citation: Pharmacol Biochem Behav. 2010 Dec;97(2):262-6
references.pmid: 20801150
references.citation: J Neurosci. 2014 Mar 19;34(12):4239-50
references.pmid: 24647944
references.citation: Pharmacol Biochem Behav. 2013 Nov;112:96-103
references.pmid: 24125784
references.citation: Psychopharmacology (Berl). 1993;111(2):207-14
references.pmid: 7870954
references.citation: Behav Neurosci. 2010 Aug;124(4):500-9
references.pmid: 20695649
references.citation: Prog Neurobiol. 1980;14(2-3):69-97
references.pmid: 6999537
references.citation: Sleep. 2010 Apr;33(4):437-44
references.pmid: 20394312
references.citation: Nat Neurosci. 2002 Dec;5(12):1327-31
references.pmid: 12426572
references.citation: Proc Natl Acad Sci U S A. 1987 Jun;84(12):4308-12
references.pmid: 3035579
references.citation: Peptides. 2005 Apr;26(4):621-9
references.pmid: 15752577
references.citation: Neuroscience. 2012 Jan 27;202:384-95
references.pmid: 22155266
references.citation: Neuroscience. 2009 Oct 20;163(3):770-80
references.pmid: 19619616
references.citation: Neuroscience. 2000;99(2):267-77
references.pmid: 10938432
references.citation: Physiol Behav. 2006 Sep 30;89(2):226-34
references.pmid: 16854442
references.citation: Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R999-R1004
references.pmid: 12907414
references.citation: Eur J Pharmacol. 1989 Sep 13;168(2):243-6
references.pmid: 2558026
references.citation: Brain Res Bull. 1993;31(3-4):397-404
references.pmid: 8490738
references.citation: Front Neuroanat. 2011 Jun 17;5:36
references.pmid: 21731559
references.citation: Proc Natl Acad Sci U S A. 1986 Mar;83(5):1523-7
references.pmid: 3006054
references.citation: Pharmacol Biochem Behav. 1984 Jul;21(1):33-8
references.pmid: 6087376
references.citation: Genes Brain Behav. 2003 Apr;2(2):80-92
references.pmid: 12884965
references.citation: Pharmacol Biochem Behav. 2008 May;89(3):345-51
references.pmid: 18281083
references.citation: Psychopharmacology (Berl). 1991;104(4):515-21
references.pmid: 1780422
references.citation: Biochem Biophys Res Commun. 2003 Jun 27;306(2):544-9
references.pmid: 12804599
references.citation: Neuropsychopharmacology. 2009 Mar;34(4):972-86
references.pmid: 18800071
references.citation: Eur J Neurosci. 2005 Dec;22(12):3229-40
references.pmid: 16367789
references.citation: Psychopharmacology (Berl). 1976 Aug 17;48(3):255-60
references.pmid: 823580
references.citation: Brain Res. 2007 Apr 20;1142:100-9
references.pmid: 17292868
references.citation: J Neurosci. 1987 Aug;7(8):2445-64
references.pmid: 3039080
references.citation: Behav Brain Res. 2009 Mar 2;198(1):252-7
references.pmid: 19041901
references.citation: Physiol Behav. 2002 Jul;76(3):365-77
references.pmid: 12117573
references.citation: Br J Pharmacol. 1979 Nov;67(3):476P-477P
references.pmid: 497588
references.citation: J Neurosci. 1999 Dec 15;19(24):11017-26
references.pmid: 10594082
references.citation: Neuropharmacology. 2013 Apr;67:176-82
references.pmid: 23164617
references.citation: Brain Res. 2010 Jan 8;1306:85-92
references.pmid: 19822132
references.citation: Neurosci Lett. 2012 Mar 9;511(2):84-8
references.pmid: 22306095
references.citation: J Pharmacol Exp Ther. 1998 May;285(2):908-14
references.pmid: 9580643
references.citation: Behav Brain Res. 2002 Dec 2;137(1-2):165-77
references.pmid: 12445722